PharmaTelevision - Roche: What they look for in a partner

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Roche: What they look for in a partner

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Paul Larsmon talks with Dan Zabrowski, Global Head of Pharma Partnering at Roche.

Filmed at BIO-Europe 2009, they discuss:

• what Roche is currently looking for in a potential partner
• business development at Roche and how it operates using the mantra “want, find, get, manage”
• new ways of working with Biotech
• at what stage Roche invests in opportunities
• Roche’s areas of interest, including stems cells, oncology, CNS and arthritis
• defining innovation
• the future of the pharmaceutical industry in the next year

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Business development at Roche and how it operates using the mantra want, find, get, manage.

Paul Larsmon:

Hello and welcome to BIO-Europe 2009 here in the Austrian capital of Vienna. With me is Dr. Dan Zabrowski, Global Head of Pharma Partnering at Roche. Dan Zabrowski, the business development Manager at Roche is famously want, find, get, manage. Now how does that, how does that work in this new world of having to operate in post global financial crisis?

Dan Zabrowski:

Well actually the, the crisis has had an impact across all elements of our business development process in terms of the want and find we've been besieged with opportunities from biotech's and venture capitalist particularly biotech's that have a relatively short amount of cash left to complete their project, on the get we continue to think about creative deals because we see that there is an opportunity for us to work win, win, win with biotech's and venture capitalist by may be working earlier with them and giving them an opportunity for an earn out earn out later on in a success scenario and on the manage front we also are very active with our current partners because in some cases they have cash issues and are looking to potentially change our agreement or modify our agreement to be able to allow them a little bit more cash flow in the short-term.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Dan Zabrowski

Global Head of Pharma Partnering

Dan Zabrowski has been the Head of Pharma Partnering since July 2007. His team is dedicated to finding the best external innovation to strengthen the Roche R&D portfolio. He has previously worked at Roche Pharma HQ, Switzerland as Global Head, Drug Regulatory Affairs and Vice President, Pharma Development, Nutley, Vice President, Drug Regulatory Affairs at Roche Pharma USA in 1995 Executive Director, Drug Regulatory Affairs and Regulatory Program Director at Syntex, USA. Associate Director, North American Regulatory Affairs Fujisawa Pharmaceuticals Company, USA and School of Pharmacy, University of Illinois " Chicago Adjunct Assistant Professor, Medicinal Chemistry and Pharmacognosy

Roche

Roche plays a pioneering role in healthcare. As an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, Roche contributes on a broad range of fronts to improving people's health and quality of life. Roche is providing the first products that are tailored to the needs of specific patient groups. Their mission today and tomorrow is to create added value in healthcare by focusing on our expertise in diagnostics and pharmaceuticals. Roche is the world leader in in-vitro diagnostics and drugs for cancer, transplantation, and active in other major therapeutic areas with a high medical need such as autoimmune diseases, inflammatory diseases, virology, metabolic disorders and diseases of the central nervous system.